Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations-Reference-Cited by-同舟云学术

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

Published:2018-05-20 Issue:3 Volume:2 Page:535-548
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Iorio Alfonso¹²^ORCID,Edginton Andrea N.³,Blanchette Victor⁴,Blatny Jan⁵,Boban Ana⁶,Cnossen Marjon⁷,Collins Peter⁸,Croteau Stacy E.⁹,Fischer Katheljin¹⁰,Hart Daniel P.¹¹,Ito Shinya¹²,Korth-Bradley Joan¹³,Lethagen Stefan¹⁴,Lillicrap David¹⁵,Makris Mike¹⁶,Mathôt Ron¹⁷,Morfini Massimo¹⁸,Neufeld Ellis J.¹⁹,Spears Jeffrey²⁰

Affiliation:

1. Department of Health Research, Methods, Evidence and Impact; McMaster University; Hamilton ON Canada

2. Department of Medicine; McMaster University; Hamilton ON Canada

3. School of Pharmacy; University of Waterloo; Waterloo ON Canada

4. Division of Hematology/Oncology; Hospital for Sick Children and Department of Pediatrics; University of Toronto; Toronto ON Canada

5. Department of Paediatric Haematology; University Hospital Brno; Brno Czech Republic

6. Department of Internal Medicine; University Hospital Center; Zagreb Croatia

7. Department of Pediatric Hematology; Erasmus University Medical Center; Sophia Children’s Hospital; Rotterdam The Netherlands

8. Arthur Bloom Haemophilia Centre; School of Medicine; University Hospital of Wales; Cardiff University; Cardiff UK

9. Boston Hemophilia Center; Boston Children’s Hospital; Boston MA USA

10. Van Creveldkliniek; University Medical Center; Utrecht University; Utrecht The Netherlands

11. The Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry; London UK

12. University of Toronto; Toronto ON Canada

13. Pfizer; Collegeville PA USA

14. Sobi; Stockholm Sweden

15. Department of Pathology & Molecular Medicine; Queen’s University; Kingston ON Canada

16. Department of Infection, Immunity& Cardiovascular Disease; University of Sheffield; Sheffield UK

17. Hospital Pharmacy-Clinical Pharmacology; Academic Medical Centre; Amsterdam The Netherlands

18. Italian Association Haemophilia Centers; Milan Italy

19. St. Jude Children’s Research Hospital; Memphis TN USA

20. Grifols; Durham NC USA

Publisher

Wiley

Subject

Hematology

Reference65 articles.

1. Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment;Berntorp;Haemophilia,2012

2. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B;Iorio;Cochrane Database Syst Rev,2011

3. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement;Iorio;Haemophilia,2017

4. Practical considerations in choosing a factor VIII prophylaxis regimen: role of clinical phenotype and trough levels;Ljung;Thromb Haemost,2016

5. Individualizing factor replacement therapy in severe hemophilia;Carcao;Semin Thromb Hemost,2015

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX–Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective–Prospective Study;Journal of Clinical Medicine;2024-03-06

2. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

3. Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis;Journal of Thrombosis and Haemostasis;2023-12

4. Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A;Thrombosis Research;2023-12

5. A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B;British Journal of Clinical Pharmacology;2023-09-12